These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35579771)

  • 61. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
    Kang HG; Kim TY; Han J; Han SH
    Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
    [TBL] [Abstract][Full Text] [Related]  

  • 62. OUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATURITY IN ZONE I.
    Yoon JM; Shin DH; Kim SJ; Ham DI; Kang SW; Chang YS; Park WS
    Retina; 2017 Jan; 37(1):88-96. PubMed ID: 27347645
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluation of Refractive Errors and Ocular Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity.
    Gunay M; Sekeroglu MA; Bardak H; Celik G; Esenulku CM; Hekimoglu E; Bardak Y
    Strabismus; 2016 Jun; 24(2):84-8. PubMed ID: 27120579
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
    Kim J; Kim SJ; Chang YS; Park WS
    Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser.
    Isaac M; Mireskandari K; Tehrani N
    J AAPOS; 2015 Apr; 19(2):140-4. PubMed ID: 25892041
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity.
    Gunay M; Celik G; Gunay BO; Aktas A; Karatekin G; Ovali F
    Arq Bras Oftalmol; 2015; 78(5):300-4. PubMed ID: 26466229
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
    Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C
    Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Structural sequelae and refractive outcome 1 year after laser treatment for type 1 prethreshold retinopathy of prematurity in Asian Indian eyes.
    Katoch D; Sanghi G; Dogra MR; Beke N; Gupta A
    Indian J Ophthalmol; 2011; 59(6):423-6. PubMed ID: 22011484
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity.
    Eftekhari Milani A; Hassanpoor N; Mousavi Mirkala M; Taheri A; Golizade A; Niyousha MR
    Int Ophthalmol; 2020 Feb; 40(2):477-482. PubMed ID: 31712928
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment.
    Chang YS; Chen YT; Lai TT; Chou HC; Chen CY; Hsieh WS; Yang CM; Yeh PT; Tsao PN
    PLoS One; 2019; 14(10):e0223972. PubMed ID: 31618256
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP.
    Anand N; Blair MP; Greenwald MJ; Rodriguez SH
    J AAPOS; 2019 Apr; 23(2):88.e1-88.e6. PubMed ID: 30797978
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
    Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
    Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Intravitreal bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence.
    Fadakar K; Mehrabi Bahar M; Riazi-Esfahani H; Azarkish A; Farahani AD; Heidari M; Bazvand F
    Int Ophthalmol; 2022 Jul; 42(7):2017-2028. PubMed ID: 35059928
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series.
    Hillier RJ; Connor AJ; Shafiq AE
    Br J Ophthalmol; 2018 Feb; 102(2):260-264. PubMed ID: 28655731
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
    Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
    Ophthalmology; 2023 Apr; 130(4):373-378. PubMed ID: 36396121
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.
    Yetik H; Gunay M; Sirop S; Salihoglu Z
    Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1677-83. PubMed ID: 25501298
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.
    Araz-Ersan B; Kir N; Tuncer S; Aydinoglu-Candan O; Yildiz-Inec D; Akdogan B; Ekici B; Demirel A; Ozmen M
    Curr Eye Res; 2015 May; 40(6):585-91. PubMed ID: 25025864
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Characteristics of Severe Retinopathy of Prematurity in Infants with Birth Weight above 1500 Grams at a Referral Center in Turkey.
    Gunay M; Celik G; Tuten A; Karatekin G; Bardak H; Ovali F
    PLoS One; 2016; 11(8):e0161692. PubMed ID: 27548628
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.
    Chung EJ; Kim JH; Ahn HS; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1727-30. PubMed ID: 17690897
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.